Seres Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| SERES THERAPEUTICS, INC. | ||
| Date: March 5, 2024 | By: | /s/ Eric D. Shaff |
|---|---|---|
| Eric D. Shaff | ||
| President, Chief Executive Officer and Director | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Eric D. Shaff | President, Chief Executive Officer | March 5, 2024 |
| Eric D. Shaff | and Director | |
| (Principal Executive Officer) | ||
| /s/ David Arkowitz | Executive Vice President, Chief Financial Officer, and Head of Business Development | March 5, 2024 |
| David Arkowitz | (Principal Financial and Accounting Officer) | |
| /s/ Stephen Berenson | Chairman of the Board | March 5, 2024 |
| Stephen Berenson | ||
| /s/ Dennis A. Ausiello | Director | March 5, 2024 |
| Dennis A. Ausiello, M.D. | ||
| /s/ Paul R. Biondi | Director | March 5, 2024 |
| Paul R. Biondi | ||
| /s/ Willard H. Dere | Director | March 5, 2024 |
| Willard H. Dere, M.D. | ||
| /s/ Claire M. Fraser | Director | March 5, 2024 |
| Claire M. Fraser, Ph.D. | ||
| /s/ Kurt C. Graves | Director | March 5, 2024 |
| Kurt C. Graves | ||
| /s/ Richard N. Kender | Director | March 5, 2024 |
| Richard N. Kender | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID 238) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-4 |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023, 2022 and 2021 | F-5 |
| Consolidated Statements of Stockholders’ (Deficit) Equity as of December 31, 2023, 2022 and 2021 | F-6 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023, 2022 and 2021 | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.